Skip to main content
CTIS.
EU
Conditions
IMPs
Countries
Sponsors
Sites
Trial Map
Safety
Transparency
Landscape
EN — English
BG — Български
CS — Čeština
DA — Dansk
DE — Deutsch
EL — Ελληνικά
ES — Español
ET — Eesti
FI — Suomi
FR — Français
GA — Gaeilge
HR — Hrvatski
HU — Magyar
IT — Italiano
LT — Lietuvių
LV — Latviešu
MT — Malti
NL — Nederlands
PL — Polski
PT — Português
RO — Română
SK — Slovenčina
SL — Slovenščina
SV — Svenska
NO — Norsk
CTIS.
EU
✕
Conditions
IMPs
Countries
Sponsors
Sites
Trial Map
Safety
Transparency
Landscape
Notice
This is an independent non-profit initiative. We are not affiliated with the European Medicines Agency (EMA) or the official CTIS system. For the official EU Clinical Trials Information System, visit:
EMA Registry →
CTIS.eu
›
Conditions
› Relapsed/Refractory B-Cell Non-Hodgkin’s Lymphoma (r/r B-cell NHL)
Relapsed/Refractory B-Cell Non-Hodgkin’s Lymphoma (r/r B-cell NHL)
1 total trials
Filter these 1 trials by phase, country, sponsor and more.
Open in Search →
A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa (RO7227166, a CD19 targeted 4-1BB l …
Recruitment ended
2022-502616-37-00
9
2019-07-30
Showing 1–1 of 1 trials